MGMT and glioblastoma: Despite early suggestion of cilengitide activity in GBM with MGMT promoter methylation [87,88], there was no survival benefit in the larger randomized Phase III ‘Cilengitide Combined With Standard Treatment for Patients With Newly Diagnosed GBM With Methylated MGMT Promoter’ (CENTRIC) trial, so development was discontinued [89].